BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12480514)

  • 1. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice.
    Chen S; Iglesias-de la Cruz MC; Jim B; Hong SW; Isono M; Ziyadeh FN
    Biochem Biophys Res Commun; 2003 Jan; 300(1):16-22. PubMed ID: 12480514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
    Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.
    Sharma K; Jin Y; Guo J; Ziyadeh FN
    Diabetes; 1996 Apr; 45(4):522-30. PubMed ID: 8603776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
    Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
    FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
    Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R
    Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
    Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
    Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice.
    Shibuya K; Kanasaki K; Isono M; Sato H; Omata M; Sugimoto T; Araki S; Isshiki K; Kashiwagi A; Haneda M; Koya D
    Diabetes; 2005 Mar; 54(3):838-45. PubMed ID: 15734863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.
    Cohen MP; Sharma K; Jin Y; Hud E; Wu VY; Tomaszewski J; Ziyadeh FN
    J Clin Invest; 1995 May; 95(5):2338-45. PubMed ID: 7738197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
    Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
    Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of decline in renal function in the diabetic db/db mouse.
    Cohen MP; Clements RS; Cohen JA; Shearman CW
    Diabetologia; 1996 Mar; 39(3):270-4. PubMed ID: 8721771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
    Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
    J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
    Okada M; Takemura T; Yanagida H; Yoshioka K
    Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chrysin Inhibits Advanced Glycation End Products-Induced Kidney Fibrosis in Renal Mesangial Cells and Diabetic Kidneys.
    Lee EJ; Kang MK; Kim DY; Kim YH; Oh H; Kang YH
    Nutrients; 2018 Jul; 10(7):. PubMed ID: 29987200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble betaglycan reduces renal damage progression in db/db mice.
    Juárez P; Vilchis-Landeros MM; Ponce-Coria J; Mendoza V; Hernández-Pando R; Bobadilla NA; López-Casillas F
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F321-9. PubMed ID: 16954341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy.
    Guo M; Ricardo SD; Deane JA; Shi M; Cullen-McEwen L; Bertram JF
    J Anat; 2005 Dec; 207(6):813-21. PubMed ID: 16367807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse.
    Bower G; Brown DM; Steffes MW; Vernier RL; Mauer SM
    Lab Invest; 1980 Oct; 43(4):333-41. PubMed ID: 7003252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors.
    Zheng F; Cornacchia F; Schulman I; Banerjee A; Cheng QL; Potier M; Plati AR; Berho M; Elliot SJ; Li J; Fornoni A; Zang YJ; Zisman A; Striker LJ; Striker GE
    Diabetes; 2004 Sep; 53(9):2420-7. PubMed ID: 15331554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.
    Chen S; Hong SW; Iglesias-de la Cruz MC; Isono M; Casaretto A; Ziyadeh FN
    Ren Fail; 2001; 23(3-4):471-81. PubMed ID: 11499562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.